Tech Company Financing Transactions
Epicrispr Biotechnologies Funding Round
Epicrispr Biotechnologies closed a $90 million Series C funding round on 8/11/2026. Investors included Janus Henderson Investors, Octagon Capital and Abrdn.
Transaction Overview
Company Name
Announced On
8/11/2026
Transaction Type
Venture Equity
Amount
$90,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to advance EPI-321, its lead clinical candidate currently in first-in-human studies for facioscapulohumeral muscular dystrophy (FSHD), accelerate its pipeline of programmable epigenetic medicines, and expand its proprietary platform and manufacturing capabilities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7000 Shoreline Court 100
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Epicrispr Biotechnologies is building the world's leading therapeutic platform based on the exciting new technology of epigenetic editing. We were founded by genetic medicine pioneer Stanley Qi, Ph.D., whose fundamental work in epigenetic editing includes the invention of CRISPRa (activation) and CRISPRi (interference). We are translating the powerful potential of epigenetic editing into transformative therapies that can expand the promise of genetic medicine and improve the lives of people with serious diseases.
Management Team
Browse more venture capital transactions:
Prev: 8/11/2026: Soor venture capital transaction
Next: 8/11/2026: FINN venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








